A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection

Transplantation

Volumn 80, Issue 3, 2005, Pages 378-384

  Akashi, Satoru ^a   Sho, Masayuki ^a   Kashizuka, Hisanori ^a   Hamada, Kaoru ^a   Ikeda, Naoya ^a   Kuzumoto, Yukiyasu ^a   Tsurui, Yoshikazu ^a   Nomi, Takeo ^a   Mizuno, Takashi ^a   Kanehiro, Hiromichi ^a   Hisanaga, Michiyoshi ^a   Ko, Saiho ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alloimmune response; Cardiac and islet transplantation; CCR5; CXCR3; Mice

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; RNA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FIBROSIS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR DISEASE;

AMIDES; ANIMALS; ANTIGENS, CD11C; ANTIGENS, CD4; ANTIGENS, CD8; CELL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 23744505807     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000166338.99933.e1     Document Type: Article

References (41)

1. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998; 338: 436.
2. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102.
3. Hancock WW, Wang L, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15: 479.
4. Hancock WW. Chemokine receptor-dependent alloresponses. Immunol Rev 2003; 196: 37.
5. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002; 14: 562.
6. Lee I, Wang L, Wells AD, et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171: 6929.
7. Belperio JA, Keane MP, Burdick MD, et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 2003; 171: 4844.
8. Abdi R, Means TK, Ito T, et al. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 2004; 172: 767.
9. Zhang Z, Kaptanoglu L, Tang Y, et al. IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 2004; 126: 809.
10. Abdi R, Smith RN, Makhlouf L, et al. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 2002; 51: 2489.
11. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199.
12. Baker MS, Chen X, Rotramel AR, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003; 134: 126.
13. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
14. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746.
15. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999; 96: 5698.
16. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955.
17. Gao P, Zhou XY, Yashiro-Ohtani Y, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 2003; 73: 273.
18. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
19. Sho M, Sandner SE, Najafian N, et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg 2002; 236: 667.
20. Gotoh M, Maki T, Kiyoizumi T, et al. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40: 437.
21. Yang YF, Mukai T, Gao P, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002; 32: 2124.
22. Este JA. TAK-779 (Takeda). Curr Opin Investig Drugs 2001; 2: 354.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
24. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
25. Markmann JF, Deng S, Huang X, et al. Insulin independence following isolated islet transplantation and single islet infusions. Ann Surg 2003; 237: 741.
26. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083.
27. McLaren AJ, Fuggle SV, Welsh KI, et al. Chronic allograft failure in human renal transplantation: a multivariate risk factor analysis. Ann Surg 2000; 232: 98.
28. Waaga AM, Gasser M, Laskowski I, Tilney NL. Mechanisms of chronic rejection. Curr Opin Immunol 2000; 12: 517.
29. Goddard S, Williams A, Morland C, et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 2001; 72: 1957.
30. Melter M, Exeni A, Reinders ME, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558.
31. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758.
32. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004; 10: 434.
33. Schroppel B, Fischereder M, Ashkar R, et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002; 2: 640.
34. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003; 75: 72.
35. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
36. Yun JJ, Fischbein MP, Laks H, et al. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001; 71: 1649.
37. Pattison JM, Nelson PJ, Huie P, et al. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996; 15: 1194.
38. Yun JJ, Whiting D, Fischbein MP, et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 2004; 109: 932.
39. Takami S, Minami M, Katayama T, et al. TAK-779, a nonpeptide CC chemokine receptor antagonist, protects the brain against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2002; 22: 780.
40. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 2003; 100: 10411.
41. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.